logo

The AIM with Immunotherapy Initiative – Home › Forums › Immunotherapy › Other › Practice volume

Viewing 2 posts - 1 through 2 (of 2 total)
  • Author
    Posts
  • February 14, 2018 at 4:24 pm #4688
    Anonymous

      Poll question-

      1) Has the FDA approval of adjuvant nivolumab impacted your practice volume? If so, can you estimate by how much. eg: 10% increase in volume

      2) Compelling data supporting adjuvant BRAF/MEK was released at the same time. Though not yet FDA approved, I know many practices are already using.
      Is your practice? IF so, has this too influenced your volume- and by how much?

      Trying to get a sense of the overall impact of these incredible practice changing events (for providers).

      Thanks

      February 15, 2018 at 3:37 pm #4689
      Anonymous

        Hi Krista,

        Great question.

        In response to #1- I would say the approval has increased our volume more in terms of new patients coming for second opinions and I’m not quite sure why. I don’t know if it is because the community is uncomfortable recommending this or patients aren’t wanting to get treatment so they come hoping we won’t recommend anything. I would say I’ve noticed a small increase in the volume of returns as we put more patients on adjuvant nivolumab.

        In response to #2- We are currently not recommending adjuvant BRAF/MEK.
        Thanks,
        Lisa

      • Author
        Posts
      Viewing 2 posts - 1 through 2 (of 2 total)
      • You must be logged in to reply to this topic.

      Latest Activity
      Copyright ©2022- - AIM with Immunotherapy. All rights reserved.